Head-to-head · WeighScore
bmiMD vs RxPros
By GLP-1 ScorecardUpdated
Score comparison
bmiMD has the higher recorded score — 79.2/100 to 69.3/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Before you choose
Before comparing the headline prices, the bmiMD review and the RxPros review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.
If neither one fits, bmiMD vs Somi Health and Candor Rx vs RxPros compare each of them with another graded program, and the list of alternatives to bmiMD ranks the programs closest to bmiMD on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | RxPros |
|---|---|---|
| WeighScore | 79.2/100 | 69.3/100 |
| Grade | C+ | C |
| Site position | #27 | #144 |
| Semaglutide | $129/mo on the one-month plan ($99/mo equivalent with $1,188 prepaid for 12 months) | $100/mo (annual plan, compounded) |
| Tirzepatide | $179/mo on the one-month plan ($139/mo equivalent with $1,668 prepaid for 12 months) | $145/mo (annual plan, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Not confirmed |
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $99 and $139 monthly equivalents require $1,188 or $1,668 paid upfront for 12 months
- A higher $229 and $349 monthly figure is printed beside every plan price under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Strengths
- $99.99/month compounded semaglutide — among the cheapest in the US compounded telehealth market
- $144.97/month compounded tirzepatide — at the lower end of the compounded tirzepatide range
- LegitScript Certified
- Named legal entity (RxPros LLC) with a physical Wyoming address
- Overnight cold-packed shipping disclosed — important for GLP-1 cold-chain integrity
What to consider
- Per-state availability not listed — verify your state ships before committing
- Specific 503A pharmacy partners not named
- Lab work not included as standard
- LegitScript certification number not displayed (seal only)
- Lowest headline prices ($99.99 sema / $144.97 tirz) require annual prepay; intro-first-month/quarterly tier is $134.99 sema / $224.99 tirz
Featured provider
bmiMD
Factor scores not reassessed.bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.